iPS Cells & Regenerative Medicine– category –
-
Advances in Multiple Myeloma Treatment: CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates Evolving in Approved & Clinical Stages
Myeloma Crowd USA Overview An article summarizing the latest advancements in multiple myeloma treatment highlights the diversification of approved and investigational approaches, including CAR-T cell therapies, bispecific T-cell engagers... -
ROKIT America Clears SEC Registration Statement for Nasdaq Listing, Raises KRW 38 Billion to Accelerate Regenerative Medicine Commercialization
Korea Biomedical Review (KBR) South Korea Overview ROKIT America has secured U.S. SEC registration statement approval for its Nasdaq listing, aiming to expand its regenerative medicine clinical programs and commercial activities across N... -
Synthetic Biology Firm Syntax Bio Expands Series A to $14.4M, Boosting Preclinical Research for CRISPR-Based Type 1 Diabetes Beta-Cell Therapy
Fierce Biotech USA Overview Synthetic biology company Syntax Bio announced an expansion of its Series A funding round to $14.4 million, pushing total capital raised over $25 million. This capital injection will primarily drive the develo... -
Regentis Biomaterials Secures $6.5M Private Placement to Accelerate Regenerative Tissue Repair Solutions
BioSpace (Press Release) イスラエル Overview Regentis Biomaterials, an innovator in regenerative medicine, has successfully closed a $6.5 million private placement, securing capital through the issuance of common shares and warrants. Thi... -
Dermatology & Plastic Surgery Specialists Introduces Exosome Therapy for Anti-Aging: Harnessing Stem Cell Culture-Derived Extracellular Vesicles for Skin Regeneration
Dermatology & Plastic Surgery Specialists (Blog) USA Overview Dermatology & Plastic Surgery Specialists has introduced exosome therapy as an anti-aging treatment. This therapy utilizes extracellular vesicles to signal skin cells for ... -
Takeda Exits Cell Therapy, Shifts Strategy to AI Drug Discovery with Additional 4,500 Job Cuts in Restructuring
BioSpace USA Overview Takeda Pharmaceutical Company is undergoing a major restructuring, including a complete exit from cell therapy, to navigate 'existential risks,' shifting its focus to 'frontier science' such as AI-driven drug discov... -
AATD Treatment Race Intensifies: Beam Therapeutics Plans Pivotal Cohort for Accelerated Approval of Base Editor BEAM-302
CRISPR Medicine News USA Overview The field of Alpha-1 Antitrypsin Deficiency (AATD) treatment is witnessing heightened competition, with five gene editing companies reporting new data and Sanofi introducing a non-edited recombinant prot... -
Cell-Free Advantage: Exosome-Biomaterial Platforms Offer Safer Treatment for Diabetic Skin Infections, But Clinical Translation Remains Complex
International Journal of Nanomedicine (論文) Global Overview A recent review explores exosome-biomaterial platforms as a promising, safer alternative to cell therapies for diabetic skin infections. These 'cell-free' approaches address sa... -
Prime Medicine’s Autologous Prime Editing Hematopoietic Stem Cell Therapy PM359 for p47phox-Deficient Chronic Granulomatous Disease Receives FDA RMAT Designation
BiopharmaWatch (Prime Medicine Press Release) USA Overview Prime Medicine announced its investigational autologous prime editing hematopoietic stem cell therapy, PM359, for the treatment of p47phox-deficient Chronic Granulomatous Disease... -
Prime Medicine Secures NZ Clinical Trial Clearance for Prime Editing Therapy PM577a in H1069Q-Mutated Wilson Disease, Initiating Global Phase 1/2 Study
GlobeNewswire (Prime Medicine Press Release) USA Overview Prime Medicine has announced the approval of its Clinical Trial Application (CTA) in New Zealand for PM577a, an investigational prime editing therapy for H1069Q-mutated Wilson dis...
